Cargando…
Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
PURPOSE: To report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex(®); Allergan, Inc, Irvine, CA) in noninfectious posterior uveitis. METHODS: A retrospective chart review of patients with noninfectious uveitis treated with sustained-release dexamethasone 0.7...
Autores principales: | Myung, Jane S, Aaker, Grant D, Kiss, Szilárd |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000767/ https://www.ncbi.nlm.nih.gov/pubmed/21188153 http://dx.doi.org/10.2147/OPTH.S15696 |
Ejemplares similares
-
Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
por: Hunter, Rebecca S, et al.
Publicado: (2011) -
Efficacy and tolerability of bilateral sustained-release dexamethasone intravitreal implants for the treatment of noninfectious posterior uveitis and macular edema secondary to retinal vein occlusion
por: Ryder, Steven J, et al.
Publicado: (2015) -
Intravitreal Dexamethasone Implants for Refractory Macular Edema in Eyes with Noninfectious Uveitis
por: Kang, Eugene Yu-Chuan, et al.
Publicado: (2021) -
Management of noninfectious posterior uveitis with intravitreal drug therapy
por: Tan, Hui Yi, et al.
Publicado: (2016) -
Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis
por: Tufail, Adnan, et al.
Publicado: (2018)